Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795048 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
A Phase 4 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 4
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT06795048 is a Phase 4 study of Neovascular Age-related Macular Degeneration (nAMD) that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 274 participants, above the 178-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06795048, a Phase 4 study of Neovascular Age-related Macular Degeneration (nAMD), is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
Conditions Studied
Interventions
- DRUG Faricimab
Study Locations (20)
Ontario
- St. Joseph's Health Care - London
- Retina Institute of Ottawa - Ottawa
- Toronto Retina Institute - Toronto
Florida
- Florida Retina Institute - Orlando
- Ctr for Retina & Macular Dis - Winter Haven
Illinois
- Retinal Vitreal Consultants - Chicago
- University Retina and Macula Associates, PC - Lemont
New South Wales
- Strathfield Retina Clinic - Strathfield
- Sydney Eye Hospital - Sydney
Victoria
- Centre For Eye Research Australia - East Melbourne
- Retina Specialists Victoria - Rowville
California
- Orange County Retina Medical Group - Santa Ana
Massachusetts
- New England Retina Consultants - Springfield
Nevada
- Sierra Eye Associates - Sparks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2027-09-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06795048
The ClinicalTrials.gov registry entry for NCT06795048 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (54% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 1 intervention - of which Faricimab is the first listed.
NCT06795048 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ontario, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06795048 about?
NCT06795048 is a clinical study titled "A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration". This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatmen...
What is the current status of trial NCT06795048?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 274 participants. The study started on 2025-03-14. Estimated completion is 2027-09-16.
What conditions does trial NCT06795048 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).
What interventions are being tested in trial NCT06795048?
The interventions under investigation include: Faricimab (DRUG).
Who is sponsoring clinical trial NCT06795048?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795048 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration (nAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
RECRUITING · Phase 3
-
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.